Oculis (NASDAQ:OCS) Trading Up 7% on Analyst Upgrade

Shares of Oculis Holding AG (NASDAQ:OCS) shot up 7% on Thursday after Guggenheim upgraded the stock to a strong-buy rating. The company traded as high as $30.25 and last traded at $29.8670. 372,065 shares traded hands during trading, an increase of 6% from the average session volume of 349,370 shares. The stock had previously closed at $27.91.

Several other analysts also recently issued reports on OCS. Wall Street Zen downgraded Oculis from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Stifel Nicolaus upped their price target on Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. JPMorgan Chase & Co. upped their price target on Oculis from $38.00 to $42.00 and gave the stock an “overweight” rating in a research note on Monday, May 18th. HC Wainwright upped their price target on Oculis from $44.00 to $47.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Finally, Needham & Company LLC upped their price target on Oculis from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.38.

Hedge Funds Weigh In On Oculis

Large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. lifted its position in shares of Oculis by 100.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after purchasing an additional 1,000 shares during the last quarter. Aventura Private Wealth LLC acquired a new position in shares of Oculis during the 4th quarter worth about $80,000. Koshinski Asset Management Inc. acquired a new position in shares of Oculis during the 1st quarter worth about $238,000. Millennium Management LLC acquired a new position in shares of Oculis during the 4th quarter worth about $312,000. Finally, Marshall Wace LLP acquired a new position in shares of Oculis during the 2nd quarter worth about $393,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Stock Down 4.9%

The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -13.85 and a beta of 0.38. The firm has a 50-day moving average of $27.48 and a two-hundred day moving average of $24.86.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.14). Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%.The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.25 million. As a group, sell-side analysts predict that Oculis Holding AG will post -2.21 earnings per share for the current fiscal year.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.